Explore the words cloud of the CRUZIVAX project. It provides you a very rough idea of what is the project "CRUZIVAX" about.
The following table provides information about the project.
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
|Coordinator Country||Germany [DE]|
|Total cost||0 €|
|EC max contribution||8˙391˙240 € (0%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-06-01 to 2024-05-31|
Take a look of project's partnership.
|1||HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH||DE (BRAUNSCHWEIG)||coordinator||2˙070˙198.00|
|2||COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES||FR (PARIS 15)||participant||963˙795.00|
|3||ASA SPEZIALENZYME GMBH||DE (WOLFENBUTTEL)||participant||951˙500.00|
|4||ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG||HU (DUNAKESZI)||participant||863˙592.00|
|5||GENIBET - BIOPHARMACEUTICALS SA||PT (OEIRAS)||participant||861˙249.00|
|6||UNIVERSIDAD DE BUENOS AIRES||AR (BUENOS AIRES)||participant||745˙500.00|
|7||UNIVERSITEIT ANTWERPEN||BE (ANTWERPEN)||participant||577˙302.00|
|8||UNIVERSIDADE NOVA DE LISBOA||PT (LISBOA)||participant||442˙206.00|
|9||INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA||PT (OEIRAS)||participant||352˙356.00|
|10||VAKZINE PROJEKT MANAGEMENT GMBH||DE (HANNOVER)||participant||310˙137.00|
|11||FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA||ES (BARCELONA)||participant||253˙401.00|
Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden in the Americas (>11,000,000 chronic infections) and the first cause of cardiac morbidity in poor rural/suburban areas. It became a worldwide concern as a result of mass migration with reports in 19 non-endemic areas (>1.3 million carriers in EU/USA). Treatment is difficult since acute infections have mild symptoms and remain largely unnoticed evolving to chronicity. Drug therapy is also long, often associated with side effects (10-30% interruption) and only active during early infection. The main objective of CRUZIVAX is to bridge the gap between preclinical and clinical development by performing preclinical and clinical phase 1 studies of a needle-free vaccine against T. cruzi with proven efficacy in preclinical models. The vaccine is based on a structure-engineered trivalent chimeric antigen lacking immune decoy sequences and an adjuvant promoting self-limited locally-restricted immune activation stimulating humoral and cellular immunity, which is expected to protect as prophylactic or therapeutic (combined with Benznidazole) vaccine. To achieve this CRUZIVAX will: (i) conduct preclinical studies in mice to assess immunogenicity and efficacy of different vaccine formulations in prophylactic and therapeutic settings, (ii) analyse the immunogenicity and efficacy of the best vaccine formulation in dogs and non-human primates, (iii) produce cGMP antigen and adjuvant by cost-efficient manufacturing (facilitated uptake by health systems with limited resources), (iv) perform a preclinical safety assessment of the vaccine, (v) conduct a phase 1 vaccine clinical trial in healthy volunteers, and (vi) carry out a health economics analysis to identify critical target-product profile parameters. The vaccine will strengthen the pipeline of products for Chagas disease, aimed at reducing disease burden and its social and economic impact.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRUZIVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CRUZIVAX" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More